Kayayyaki

Hanyoyin da za a bi don magance T2DM, cutar da ke da lahani biyu na rashin aikin sel na islet da kuma juriya na insulin, sun haɗa da wakilai waɗanda ke ƙara haɓakar insulin ta hanyar pancreas (masu asiri), wakilan da ke ƙara yawan hankali ga gabobin da ake nufi da insulin (masu saurara), da kuma Liraglutide, GLP-1 agonist mai karɓa don isa kasuwa, yana da 97% homology zuwa GLP-1 tare da canje-canjen amino acid guda biyu kawai da ƙari na sarkar gefen fatty acid.Musamman, an maye gurbin lysine a matsayi na 34 tare da arginine, kuma an gyara lysine a matsayi na 26 tare da sarkar C16 acyl ta hanyar glutamoyl spacer.Liraglutide yana samun juriya ga lalacewar DPP-4 daga haɓakar sa don samar da miceles da ɗaure ga albumin.Ba kamar wanda ya riga shi exenatide ba, wanda ke buƙatar allurar subcutaneous sau biyu a rana kafin abinci na farko da na ƙarshe na rana, an yarda da liraglutide azaman tsarin jiyya na yau da kullun kuma ana iya amfani dashi tare da metformin ko sulfonylurea a cikin marasa lafiya tare da ƙarancin sarrafa glycemic tare da ko dai. monotherapy ko hade biyu far.Hakanan an yarda da shi tare da maganin dual na metformin da thiazolidinedione a cikin marasa lafiya waɗanda ke da ƙarancin sarrafa glycemic.Liraglutide ya nuna ƙarfin ɗauri na 61 pM (EC50 = 55 pM don GLP-1) don mai karɓa na GLP-1 ɗan adam.